secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001437749-24-031966
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex partners with U Michigan to study REQORSA plus ALK-inhibitors in ALK+ lung cancer
--------------------------------------------------------------------------------

- Entered Sponsored Research Agreement with Univ. of Michigan Rogel Cancer Center for TUSC2/REQORSA combo with ALK-inhibitors.
- Collaboration with ALK Positive nonprofit; both share cost of the SRA.
- Preclinical data (AACR Apr 2024): REQORSA induced apoptosis in alectinib-resistant EML4-ALK+ NSCLC lines.
- TUSC2 overexpression via REQORSA decreased cell growth and proliferation through apoptotic pathway activation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924031966/0001437749-24-031966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924031966/gnpx20241002_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer